Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is an experimental small molecule with the molecular formula C19H11ClF3N5O2 and a molecular weight of approximately 433.8 g/mol. It is not approved for clinical use in any country and has no known brand names or marketed indications. The compound acts as an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), with reported IC50 values in the low nanomolar range (IC50 ≈ 353 nM). VEGFR2 inhibition suggests potential antiangiogenic activity relevant to oncology and other diseases involving pathological angiogenesis. There are no records of advanced clinical trials or commercial development for this molecule as a drug product[1][4][5].
- Other names
- 6-chloro-N-(pyrimidin-5-yl)-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzoxazole-7-carboxamide6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide6-chloro-N-pyrimidin-5-y1–3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole–7-carboxamide
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide.